Leukemia, Myeloid, Acute research hub
24 indexed studies · 16 currently recruiting
- enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
Australia · Belgium · Denmark - recruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
United States · Belgium · Canada - recruitingPHASE3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
This study looks at a new drug, Elritercept, for adults with a type of blood disorder called Myelodysplastic Syndromes (MDS). It aims to see if Elritercept can reduce the need for regular blood transfusions and how safe it is.
United States · Australia · Brazil - active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
This study compares a new medicine, luspatercept, with a standard one, epoetin alfa, for people with a type of blood disorder called myelodysplastic syndromes (MDS). It aims to see if luspatercept can reduce the need for blood transfusions.
United States · Australia · Austria - recruiting
Red blood cell transfusion schedule in myelodysplastic syndromes
This UK clinical trial is testing a new way of giving blood transfusions to adults with myelodysplastic syndromes (MDS). Instead of having larger transfusions every three to four weeks, participants try smaller, weekly transfusions for six weeks to see if this keeps energy levels steadier and improves quality of life.
United Kingdom · England - recruitingPHASE2
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
This study is testing a new drug called momelotinib for people with a type of blood disorder called low-risk myelodysplastic syndromes (LR-MDS). Researchers want to see if it's safe, helps reduce the need for blood transfusions, and how the body handles the medicine.
United States · Canada · France - recruiting
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
This study checks if people with certain blood conditions (MDS) can use a special smart ring to track their health. It aims to see if the ring is easy to use and if its information matches how patients feel.
Canada - recruiting
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
This study aims to understand childhood blood cancers called Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukaemia (JMML) better. Researchers want to improve diagnosis and learn more about how these conditions affect children, including their development and how different treatments work.
Germany - recruitingPHASE1, PHASE2
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
This study is testing a new medicine, ABD-3001, for adults with certain types of leukaemia (AML) or bone marrow conditions (MDS) that haven't responded to other treatments. It will check if the medicine is safe, how much can be given, and if it shows early signs of helping.
France - active not recruitingPHASE2
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
This study is testing a new medicine, tebapivat, for people with a type of bone marrow condition called lower-risk myelodysplastic syndromes (LR-MDS). It aims to see if tebapivat can reduce the need for blood transfusions.
United States · Australia · Austria - recruitingPHASE1, PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.
Australia · Netherlands · United Kingdom - enrolling by invitationPHASE2
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
This study is for people who are already taking a medicine called ASTX727 for certain blood cancers (like acute myeloid leukaemia, chronic myelomonocytic leukaemia, or myelodysplastic syndromes) in other studies, and it's helping them. It’s a way to keep taking the medicine and gather long-term safety information.
United States · Armenia · Austria - active not recruitingPHASE3
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
This study looks at a medicine called Luspatercept for people with a lower-risk type of Myelodysplastic Syndrome (MDS). We want to see if it's safe and helps reduce the need for blood transfusions.
United States · Belgium · Czechia - recruiting
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
This study looks at a new way to help diagnose Myelodysplastic Syndromes (MDS), a blood condition. Researchers are testing if a blood test called 'flow cytometry' can help tell the difference between MDS and other conditions, possibly reducing the need for bone marrow tests.
France - recruitingPHASE2
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
This study looks at whether a medicine called tranexamic acid can help stop bleeding in people with certain blood cancers like MDS and AML. Some patients will get the medicine, others a dummy pill. We want to see if it safely reduces bleeding problems.
Canada - active not recruitingPHASE3
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
This study looks at a new medicine called Luspatercept for adults with a certain type of blood disorder (MDS) who have anaemia but don't yet need blood transfusions. It compares Luspatercept to another common medicine, Epoetin Alfa, to see which is better and safer.
United States · Argentina · Australia - active not recruitingPHASE2, PHASE3
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This study is testing a new drug called imetelstat for certain types of Myelodysplastic Syndromes (MDS). It aims to see if the drug can help reduce the need for blood transfusions and is safe to use for people whose current treatment hasn't worked.
United States · Belgium · Canada - active not recruitingPHASE3
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
This study is looking at a new medicine called Luspatercept for people with a type of blood condition called Myelodysplastic Syndromes (MDS). It wants to see how well it works and if it's safe for patients who haven't responded to other treatments.
Austria · Germany · Spain - recruitingPHASE2
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
This study looks at a new medicine called elritercept for adults with a blood condition called Myelodysplastic Syndromes (MDS) who also have anaemia. We want to see how safe it is, how well people tolerate it, and if it helps their bodies make more healthy red blood cells.
United States · Australia · Czechia - active not recruitingPHASE2
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
This study looks at a new drug, imetelstat, for people with specific types of blood cancer (high-risk MDS or AML) whose previous treatments haven't worked well. It aims to see how effective and safe imetelstat is in improving blood conditions.
Australia · France · Germany - active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
United States · Finland · United Kingdom - recruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
United States · Canada · Czechia - recruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
United Kingdom - recruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
United States · Australia · China